TKIs, such as lenvatinib and cabozantinib, inhibit VEGF and its receptor signaling, thereby reducing pathological angiogenesis and partially normalizing tumor vasculature and immunosuppression within the TME [2]. This evidence concerns the gene VEGFA and neoplasm.